BrightPath Biotherapeutics Co (4594.T) Stock Price
BrightPath Biotherapeutics Co Price
Revenue at BrightPath Biotherapeutics Co has contracted by 54.0% per year over the past 12 years to 84,000.00 JPY. BrightPath Biotherapeutics Co's net margin stands at -1,553,513.2%, down from -9,632.6% several years earlier.
BrightPath Biotherapeutics Co stock price
BrightPath Biotherapeutics Co business model & stock analysis
Frequently asked questions about BrightPath Biotherapeutics Co
Converted at the current exchange rate, the BrightPath Biotherapeutics Co share trades at 0.25 EUR (45.00 JPY).
The revenue of BrightPath Biotherapeutics Co is 84,000.00 JPY. This figure is based on current financial data and reflects the company's business performance.
The profit of BrightPath Biotherapeutics Co is -1.30 B JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BrightPath Biotherapeutics Co is currently -4.79. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BrightPath Biotherapeutics Co stock.
The price-to-sales ratio (P/S) of BrightPath Biotherapeutics Co is currently 74,406.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BrightPath Biotherapeutics Co stock.
The Eulerpool Quality Score for BrightPath Biotherapeutics Co is 2/10.
The ISIN of BrightPath Biotherapeutics Co is JP3274140007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of BrightPath Biotherapeutics Co is 4594.T. The ticker symbol is used to trade BrightPath Biotherapeutics Co shares on the stock exchange.
BrightPath Biotherapeutics Co stock
BrightPath Biotherapeutics Co Peer Group
BrightPath Biotherapeutics Co FIGI
All fundamentals and in-depth analysis of BrightPath Biotherapeutics Co
Our stock analysis for BrightPath Biotherapeutics Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BrightPath Biotherapeutics Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.